BioMarin Pharmaceutical Revenue and Competitors
Estimated Revenue & Valuation
- BioMarin Pharmaceutical's estimated annual revenue is currently $1.9B per year.
- BioMarin Pharmaceutical's estimated revenue per employee is $453,765
- BioMarin Pharmaceutical's total funding is $585.8M.
- BioMarin Pharmaceutical's current valuation is $16.6B. (January 2022)
Employee Data
- BioMarin Pharmaceutical has 4077 Employees.
- BioMarin Pharmaceutical grew their employee count by 2% last year.
BioMarin Pharmaceutical's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman/CEO | Reveal Email/Phone |
2 | Chairman and CEO | Reveal Email/Phone |
3 | Group VP, Pharmacovigilance & Clinical Medical Writing | Reveal Email/Phone |
4 | Group VP, Data Science | Reveal Email/Phone |
5 | Group VP, Intellectual Property | Reveal Email/Phone |
6 | VP | Reveal Email/Phone |
7 | CIO | Reveal Email/Phone |
8 | Chief Staff to the President Worldwide Research & Development | Reveal Email/Phone |
9 | VP | Reveal Email/Phone |
10 | Group VP, BioMarin Fellow | Reveal Email/Phone |
BioMarin Pharmaceutical Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is BioMarin Pharmaceutical?
BioMarin Pharmaceutical Inc. develops enzyme therapies to treat debilitating, life-threatening genetic diseases and other indications. The Company has two enzyme replacement therapies in clinical trials and recently filed an application to enter a third enzyme into the clinic. Aldurazyme, a joint venture with Genzyme General, is an enzyme replacement therapy in a 45 patient, double-blind, placebo-controlled Phase III clinical trial to treat Mucopolysaccharidosis I (MPS I), a life-threatening genetic disease. On July 20, 2001, the Company completed the 24 week treatment stage of its Phase I clinical trial of rhASB, an enzyme replacement therapy for the treatment of MPS VI, a disease clinically similar to MPS I. Aldurazyme and rhASB have both received fast track status from the FDA, and they have also each been granted orphan designations in the U.S. and EU. The Company is also developing Vibriolysin Topical, an enzymatic gel for wound debridement (cleaning) in serious burn patients.
keywords:N/A
$585.8M
Total Funding
4077
Number of Employees
$1.9B
Revenue (est)
2%
Employee Growth %
$16.6B
Valuation
N/A
Accelerator
BioMarin Pharmaceutical News
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening...
... about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance,...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET. Company Participants.
SAN RAFAEL, Calif., July 21, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its open-label Phase 1/2 study during an oral presentation ...
SAN RAFAEL, Calif., July 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1, during an oral p ...
Other Companies in San Rafael
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4210M | 15352 | 0% | N/A |